Miami’s transformation into a legitimate tech hub has been one of the more consequential geographic shifts in American business over the past five years.
The Surprising Vanguard ETF That Is Soaring Past Tech Funds This Year
Tech stocks appear to have fallen out of favor with investors this year. Concerns about not only high valuations but excessive spending on artificial
Uranium Energy (UEC) Stock Jumps 4% Following Impressive Q2 Results
Uranium Energy (UEC) stock jumped 4% after reporting Q2 revenue of $20.2M and selling uranium at $101/lb, exceeding spot prices by over 25%.
Why Uranium Energy Stock Popped Today
Uranium spot prices averaged $80.76 per pound in Q2, and are sitting at $85.90 per pound today, according to data from TradingEconomics.com. Uranium Energy,
Ben McKenzie Investigates the Cryptocurrency Industry in Trailer for “Everyone Is Lying to You for Money ”(Exclusive)
Ben McKenzie is taking the cryptocurrency industry head-on. In the first trailer for his documentary Everyone Is Lying to You for Money, The O.C.
Tech mega-bull Dan Ives shares 10 top stock picks for weathering geopolitical turmoil
Wedbush’s Dan Ives is one of the AI trade’s loudest bulls. He lists 10 tech stocks that can weather geopolitical headwinds amid war in
5-star analyst revamps Micron stock price target before earnings
Micron stock isn’t trading cheaply, and, according to Seeking Alpha, it’s trading at nearly 33 times non-GAAP earnings, the sector median of 22.52, and
Valero Energy (VLO) and Baker Hughes (BKR) Stocks Surge While First Solar (FSLR) Sinks in 2026
Valero Energy (VLO) and Baker Hughes (BKR) stocks are up roughly 33% and 32% year-to-date in 2026, respectively, driven by oil price tailwinds, refining
Why retirees are turning to gold as a buffer against stock market losses
It’s likely not surprising that the markets have been a roller coaster of a ride the last few years, with crypto, stocks, bonds, and
QURE stock’s relentless rally continues today — here’s why HC Wainwright is bullish on uniQure
・H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130. ・The firm stated that it has “continued